What targeted therapies are available for Melanoma

Targeted Therapies for Melanoma

Targeted therapies are drugs designed to attack specific features of cancer cells—like particular genetic mutations—rather than attacking all fast-growing cells like chemotherapy does. This approach often means fewer side effects on healthy cells.

The Main Targeted Therapy Approach: BRAF Mutations

The most important targeted therapy option for melanoma focuses on a specific genetic mutation called BRAF V600. According to the NCCN Guidelines for Patients: Melanoma (2025), this is a mutation that can cause normal cells to become cancerous and is commonly found in melanomas.

Dabrafenib/Trametinib Combination

When melanoma has a BRAF V600 mutation, the preferred targeted therapy is a combination of two drugs:

• Dabrafenib – targets the BRAF mutation directly
• Trametinib – works alongside dabrafenib to block another pathway that helps cancer cells grow

This combination is FDA-approved and appears throughout the NCCN Guidelines as an option for:

• Stage 3 (regional) melanoma – as adjuvant therapy (treatment after surgery to prevent recurrence)
• Recurrent melanoma – when cancer returns
• Stage 4 (metastatic) melanoma – when cancer has spread to distant parts of the body

How Doctors Decide on Targeted Therapy

According to NCCN Guidelines, oncologists typically consider targeted therapy when:

1. Testing confirms a BRAF V600 mutation – Your melanoma must have this specific genetic change for targeted therapy to work effectively
2. The cancer is at a stage where it's appropriate – Targeted therapy may be used before surgery (neoadjuvant), after surgery (adjuvant), or as primary treatment for advanced disease
3. Other factors are evaluated – Your overall health, previous treatments, and whether you've already received immunotherapy all influence the decision

Targeted Therapy vs. Immunotherapy

It's important to understand that targeted therapy is different from immunotherapy (like checkpoint inhibitors such as nivolumab or pembrolizumab). According to the NCCN Guidelines:

• Targeted therapy attacks the cancer cell's specific mutation
• Immunotherapy helps your immune system recognize and kill cancer cells

Your doctor may recommend one approach or sometimes a combination, depending on your specific situation.

Important Questions to Ask Your Care Team

Since targeted therapy decisions depend heavily on your individual case, consider asking:

1. "Does my melanoma have a BRAF V600 mutation?" – This test result determines if targeted therapy is an option for you
2. "Is dabrafenib/trametinib recommended for my stage and situation?" – Your doctor will explain why this is or isn't the best choice for you
3. "How does targeted therapy compare to immunotherapy for my case?" – Understanding the pros and cons helps you make informed decisions
4. "What are the side effects I should expect?" – Different people experience different side effects
5. "Will I need imaging or blood tests to monitor how well the treatment is working?" – Understanding follow-up care helps you prepare

Key Takeaway

Targeted therapy with dabrafenib/trametinib is a powerful option if your melanoma has a BRAF V600 mutation. However, your oncologist will determine whether this is the most appropriate approach for your specific stage, overall health, and treatment history. The NCCN Guidelines emphasize that treatment decisions should be individualized based on your complete clinical picture.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.